Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Heigener

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Onkologie|March 31, 2011
Non-small cell lung cancer in never-smokers: a new disease entity?David F Heigener
Nature Reviews. Clinical Oncology|November 22, 2017
Lung cancer in 2017: Giant steps and stumbling blocksDavid F Heigener, Martin Reck
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
CrizotinibDavid F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…David F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2017
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?David F Heigener, Martin Reck
Drugs|November 22, 2019
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?David F Heigener, Martin Reck
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
CrizotinibDavid F Heigener, Martin Reck
Advances in Therapy|December 25, 2010
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinibDavid F Heigener, Martin Reck
Journal of Thoracic Disease|June 29, 2018
Advanced non-small cell lung cancer: the role of PD-L1 inhibitorsDavid F Heigener, Martin Reck
Medizinische Klinik (Munich, Germany : 1983)|December 14, 2007
[Non-small cell lung cancer - diagnostics and stage-adapted therapy]David F Heigener, Martin Reck, Ulrich Gatzemeier
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Onkologie|March 31, 2011
Non-small cell lung cancer in never-smokers: a new disease entity?David F Heigener
Nature Reviews. Clinical Oncology|November 22, 2017
Lung cancer in 2017: Giant steps and stumbling blocksDavid F Heigener, Martin Reck
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
CrizotinibDavid F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…David F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2017
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?David F Heigener, Martin Reck
Drugs|November 22, 2019
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?David F Heigener, Martin Reck
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
CrizotinibDavid F Heigener, Martin Reck
Advances in Therapy|December 25, 2010
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinibDavid F Heigener, Martin Reck
Journal of Thoracic Disease|June 29, 2018
Advanced non-small cell lung cancer: the role of PD-L1 inhibitorsDavid F Heigener, Martin Reck
Medizinische Klinik (Munich, Germany : 1983)|December 14, 2007
[Non-small cell lung cancer - diagnostics and stage-adapted therapy]David F Heigener, Martin Reck, Ulrich Gatzemeier
Pageof 3